Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung cancer (NSCLC) and how ...
In small cell lung cancer (SCLC), the protein DLL3 is a promising target in the development of emerging therapies. In particular, DLL3-targeted therapies have been integral in ant ...
Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...
The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...
Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...
Iberdomide is a member of a new drug class in myeloma known as CELMoD agents, which build on the established platform of ...
The US FDA has approved imlunestrant (Inluriyo) for the treatment of adult patients with estrogen receptor (ER)-positive, ...
A machine learning model enhances treatment decisions for hepatocellular carcinoma, optimizing survival outcomes through ...
The evERA study reveals promising results for giredestrant in treating advanced ER-positive breast cancer, enhancing ...
FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...
The JAVELIN Bladder 100 trial established avelumab (Bavencio) as a standard switch maintenance therapy, according to Grivas.
Daratumumab-based regimens show significant clinical benefits for newly diagnosed, transplant-ineligible multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback